loader
Please Wait
Applying Filters...

Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about E7090, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    E7090

    DEVELOPMENTS

    PRICE INFORMATION

    PharmaCompass

    Inke S.A: APIs manufacturing plant.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    2D Structure
    1. Also known as: E-7090, Tasurgratinib, E7090, 1622204-21-0, Tn7cud1nga, 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamido)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-n-methyl-1h-indole-1-carboxamide
    Molecular Formula
    C32H37N5O6
    Molecular Weight
    587.7  g/mol
    InChI Key
    IBHOLSBDZMIPPT-UHFFFAOYSA-N
    FDA UNII
    TN7CUD1NGA
    Tasurgratinib is an inhibitor of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway, with potential antineoplastic activity. Upon administration, tasurgratinib selectively interferes with the binding of FGF to FGFR through an as of yet not fully elucidated mechanism. This inhibits FGFR-mediated signaling and leads to both cell proliferation inhibition and cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation, and survival; its expression is upregulated in many tumor cell types.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    5-[2-[[4-[1-(2-hydroxyethyl)piperidin-4-yl]benzoyl]amino]pyridin-4-yl]oxy-6-(2-methoxyethoxy)-N-methylindole-1-carboxamide
    2.1.2 InChI
    InChI=1S/C32H37N5O6/c1-33-32(40)37-14-10-25-19-29(28(21-27(25)37)42-18-17-41-2)43-26-7-11-34-30(20-26)35-31(39)24-5-3-22(4-6-24)23-8-12-36(13-9-23)15-16-38/h3-7,10-11,14,19-21,23,38H,8-9,12-13,15-18H2,1-2H3,(H,33,40)(H,34,35,39)
    2.1.3 InChI Key
    IBHOLSBDZMIPPT-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO
    2.2 Other Identifiers
    2.2.1 UNII
    TN7CUD1NGA
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. E-7090

    2. Tasurgratinib

    3. E7090

    4. 1622204-21-0

    5. Tn7cud1nga

    6. 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamido)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-n-methyl-1h-indole-1-carboxamide

    7. 1h-indole-1-carboxamide, 5-((2-((4-(1-(2-hydroxyethyl)-4-piperidinyl)benzoyl)amino)-4-pyridinyl)oxy)-6-(2-methoxyethoxy)-n-methyl-

    8. 5-((2-(((4-(1-(2-hydroxyethyl)piperidin-4-yl)phenyl)carbonyl)amino)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-n-methyl-1h-indole-1-carboxamide

    9. 5-[2-[[4-[1-(2-hydroxyethyl)piperidin-4-yl]benzoyl]amino]pyridin-4-yl]oxy-6-(2-methoxyethoxy)-n-methylindole-1-carboxamide

    10. Unii-tn7cud1nga

    11. Tasurgratinib [inn]

    12. Chembl3686884

    13. Schembl15955142

    14. Gtpl11414

    15. Bdbm142256

    16. E-7090 [who-dd]

    17. Bcp29727

    18. Ex-a2908

    19. Nsc806388

    20. Nsc-806388

    21. Sb18854

    22. Example 22 [wo2014129477a1]

    23. Hy-101466

    24. Cs-0021430

    25. E 7090; E7090

    26. Us8933099, 22

    27. Q27896113

    28. 1-(2-hydroxyethyl)-7-(2-methoxyethoxy)-n-methyl-3- Oxo-7h-6-oxa-4-aza-7(5)-indola-5(2,4)-pyridina-1(4)-piperidina-2(1,4)-benzenaheptaphane-7-carboxamide

    2.4 Create Date
    2014-10-06
    3 Chemical and Physical Properties
    Molecular Weight 587.7 g/mol
    Molecular Formula C32H37N5O6
    XLogP33.1
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count11
    Exact Mass587.27438392 g/mol
    Monoisotopic Mass587.27438392 g/mol
    Topological Polar Surface Area127 Ų
    Heavy Atom Count43
    Formal Charge0
    Complexity880
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    Post Enquiry
    POST ENQUIRY